<DOC>
	<DOCNO>NCT01506141</DOCNO>
	<brief_summary>Elaprase , large molecular protein , expect cross blood brain barrier administer intravenously . A revised formulation idursulfase , idursulfase-IT , differs intravenous ( IV ) formulation , Elaprase , develop suitable delivery cerebrospinal fluid ( CSF ) via intrathecal administration . This extension study HGT-HIT-045 design collect long-term safety data pediatric patient Hunter syndrome cognitive impairment receive intrathecal idursulfase-IT intravenous Elaprase enzyme replacement therapy .</brief_summary>
	<brief_title>Extension HGT-HIT-045 Evaluating Long-Term Safety Clinical Outcomes Idursulfase ( IT ) Conjunction With Elaprase Pediatric Patients With Hunter Syndrome Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Patient must complete study requirement end study assessment study HGTHIT045 prior enrol Study HGTHIT046 must safety medical issue contraindicate participation . The patient 's parent ( ) legally authorize guardian ( ) must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) patient 's assent , relevant , must obtain . That patient receive tolerated minimum 12 month treatment weekly IV infusion Elaprase receive 80 % total planned infusion within last 6 month . Patient receive treatment investigational drug ( idursulfaseIT ) device within 30 day prior study entry . Patient unable comply protocol ( eg , unable return safety evaluation , otherwise unlikely complete study ) determine investigator . Patient experience adverse reaction study drug Study HGTHIT045 contraindicate treatment intrathecal idursulfaseIT . Patient known hypersensitivity component idursulfaseIT . For patient previously untreated intrathecal idursulfaseIT Study HGTHIT045 , patient open CSF pressure upon lumbar puncture exceed 30.0 cm H2O</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS II</keyword>
	<keyword>MPS 2</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>mp symptom</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>elaprase</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>MPS2</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>mp society</keyword>
	<keyword>MPSII</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>hunter syndrome</keyword>
	<keyword>ert treatment</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>hunter disease</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>idursulfase</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
</DOC>